Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2616434 | 0.83 | NAPRT (0.41) | NAPRTKCNA5KCNH2PLCG1KDM4E | |
| SCHEMBL16472118 | 0.83 | NAPRT (0.41) | NAPRTKCNA5KCNH2PLCG1KDM4E | |
| SCHEMBL2083721 | 0.77 | P2RX7 (0.39) | PLCG1L3MBTL1SMN1; SMN2KDM4EKMT2A | |
| SCHEMBL22023658 | 0.76 | NAPRT (0.36) | NAPRTKCNA5KCNH2PLCG1SMN1; SMN2 | |
| SCHEMBL610024 | 0.76 | EPHX2 (0.44) | NAPRTKCNA5KCNH2KMT2AALDH1A1 | |
| SCHEMBL31009386 | 0.76 | EPHX2 (0.44) | NAPRTKCNA5KCNH2KMT2AALDH1A1 | |
| SCHEMBL1804567 | 0.75 | TRIM24 (0.39) | PLCG1L3MBTL1SMN1; SMN2GAAKDM4E | |
| SCHEMBL21166180 | 0.75 | CA2 (0.37) | PLCG1L3MBTL1SMN1; SMN2GAAKDM4E | |
| SCHEMBL1817604 | 0.75 | NOS3 (0.48) | NAPRTPLCG1L3MBTL1SMN1; SMN2GAA | |
| SCHEMBL30137376 | 0.75 | SMN1; SMN2 (0.42) | PLCG1L3MBTL1SMN1; SMN2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203076-A1 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION | 2023-06-29 | — | — | US | disclosed |
| US-20230203076-A1 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION | 2023-06-29 | — | — | US | disclosed |
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | E-THERAPEUTICS PLC (GB) | 2021-03-30 | — | — | US | disclosed |
| US-20200347085-A1 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION | 2020-11-05 | — | — | US | disclosed |
| US-9975876-B2 | 2-pyridyloxy-3-ester-4-ether orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2018-05-22 | — | — | US | disclosed |
| US-9768397-B2 | Phenylenediamine compounds for phosphorescent diazaborole metal complexes | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2017-09-19 | — | — | US | disclosed |
| US-9768397-B2 | Phenylenediamine compounds for phosphorescent diazaborole metal complexes | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2017-09-19 | — | — | US | disclosed |
| US-9768397-B2 | Phenylenediamine compounds for phosphorescent diazaborole metal complexes | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2017-09-19 | — | — | US | disclosed |
| EP-2927300-B1 | PHENYLENEDIAMINE COMPOUNDS FOR PHOSPHORESCENT DIAZABOROLE METAL COMPLEXES | COMMW SCIENT IND RES ORG (AU) | 2016-11-16 | — | — | EP | disclosed |
| EP-2927300-B1 | PHENYLENEDIAMINE COMPOUNDS FOR PHOSPHORESCENT DIAZABOROLE METAL COMPLEXES | COMMW SCIENT IND RES ORG (AU) | 2016-11-16 | — | — | EP | disclosed |
| US-20150280144-A1 | PHENYLENEDIAMINE COMPOUNDS FOR PHOSPHORESCENT DIAZABOROLE METAL COMPLEXES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2015-10-01 | — | — | US | disclosed |
| US-20150280144-A1 | PHENYLENEDIAMINE COMPOUNDS FOR PHOSPHORESCENT DIAZABOROLE METAL COMPLEXES | COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (AU) | 2015-10-01 | — | — | US | disclosed |
| WO-2015088864-A1 | 2-PYRIDYLOXY-3-ESTER-4-ETHER OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2014176144-A1 | 2-HYDROXYMETHYL-SUBSTITUTED OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2014-10-30 | — | — | WO | disclosed |
| US-8541444-B2 | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-09-24 | — | — | US | disclosed |
| US-8119658-B2 | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110288051-A1 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-11-24 | — | — | US | disclosed |
| EP-2205598-A1 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | Bristol-Myers Squibb Company (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090093516-A1 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-09 | — | — | US | disclosed |
| WO-2009045753-A1 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961238-B2 | Modulators of hedgehog (Hh) signaling pathway | SHH, GLI1, SMO | NAPRT 3871/4885KCNA5 4795/4885KCNH2 4799/4885 |
| US-20150280144-A1 | PHENYLENEDIAMINE COMPOUNDS FOR PHOSPHORESCENT DIAZABOROLE METAL COMPLEXES | DDT, PNMT, DDC | NAPRT 941/4885KCNA5 1183/4885KCNH2 1003/4885 |
| US-20090093516-A1 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | HSD3B1, HSD11B1, HSD17B1 | NAPRT 2560/4885KCNA5 1416/4885KCNH2 741/4885 |
| US-20200347085-A1 | Organic electroluminescent materials and devices | SSB, ADORA3, SNRPA1 | NAPRT 2918/4885KCNA5 1403/4885KCNH2 1246/4885 |
| US-20110288051-A1 | TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | HSD3B1, HSD11B1, HSD17B1 | NAPRT 2560/4885KCNA5 1416/4885KCNH2 741/4885 |
| US-20230203076-A1 | Organic electroluminescent materials and devices | SSB, ADORA3, SNRPA1 | NAPRT 2918/4885KCNA5 1403/4885KCNH2 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.